Sue Gail Eckhardt - 14 Feb 2025 Form 4 Insider Report for EXELIXIS, INC. (EXEL)

Role
Director
Signature
/s/ Nina Ayer, Attorney in Fact
Issuer symbol
EXEL
Transactions as of
14 Feb 2025
Net transactions value
-$225,884
Form type
4
Filing time
19 Feb 2025, 20:31:05 UTC
Previous filing
07 Jun 2024
Next filing
30 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EXEL Common Stock Options Exercise $179,227 +7,712 +23% $23.24 41,974 14 Feb 2025 Direct F1
transaction EXEL Common Stock Sale $269,997 -7,712 -18% $35.01 34,262 14 Feb 2025 Direct F1, F2
transaction EXEL Common Stock Sale $135,114 -3,856 -11% $35.04 30,406 14 Feb 2025 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EXEL Option (right to buy) Options Exercise $0 -7,712 -25% $0.000000 23,136 14 Feb 2025 Common Stock 7,712 $23.24 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 30,406 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock.
F2 Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $34.37 to $35.23. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.
F3 Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $34.95 to $35.20. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
F4 The option, representing the right to purchase a total of 30,848 shares of Common Stock, became fully exercisable on January 5, 2024.